A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is aimed at evaluating the safety and effectiveness of PCV chemotherapy in patients with recurrent high-grade glioma with IDH1/2 mutation.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hebei Yanda Hospital
• Collaborator: Beijing Tiantan Hospital
• Treatments: Lomustine; Procarbazine; Vincristine

Criteria

Inclusion Criteria:

• A diagnosis of high-grade glioma was established by pathological method,and the recurrency of the disease is ongoing.

• The report of the pathological diagnosis contained the status of IDH gene, and showed that IDH1/2 mutation existed.

• The age of the patient is between 18 years old and 70 years old.

• The condition of the patient permits the procedure of chemotherapy using PCV schema.

• The patient is informed consent, and willing to join in this research.

Exclusion Criteria:

• The diagnosis is not recurrent high-grade glioma.

• The diagnosis of high-grade glioma was not established by pathological method.

• No molecular neuropathological report is available, or the report showed that IDH1/2 mutation did not exist.

• The age of the patient does not meet the requirement of this research.

• The condition of the patient does not permit the procedure of chemotherapy using PCV schema.

• There are other conditions that the clinicians believe that the PCV chemotherapy is not appropriate for the patient.

• The patient is not willing to join in this research.